资讯
Background Development of diffuse-type gastric cancer (DGC) starts with intramucosal lesions that are primarily composed of ...
life-threatening nature of diffuse gastric cancer and the potential of SIGX1094 to address this critical medical need," said Dr. Haisheng Zhang, founder and CEO of Signet Therapeutics.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果